Many studies have revealed that CD13 is related with various kinds of cancers such as melanoma, colon cancer, prostate cancer, lung cancer, liver cancer, leukemia, thyroid cancer, etc. [9–14] Therefore, an efficient leading compound inhibiting CD13 can be exploited therapeutically. This evidence concerns the gene ANPEP and lung carcinoma.